TNFRSF18 and glioblastoma: The activation of GITR leads to an alleviation in Treg cell-mediated suppression of anti-tumor immune response and an activation of NK cells (Hanabuchi et al., 2006), inducing potent anti-tumor effector cells in GBM (Amoozgar et al., 2021).